Project description
Real-time bacterial diagnosis in neonates
Neonatal infections constitute a significant health concern as they may be fatal unless treated promptly. Diagnosis, however, relies on conventional microbiology techniques that are laborious and prone to human error. Funded by the Marie Skłodowska-Curie Actions programme, the FIT-BI project aims to develop rapid diagnostic kits that allow the real-time identification of multiple bacteria. Moreover, these solutions will facilitate the prediction of antimicrobial susceptibility and help avoid excessive antibiotic use and the development of antimicrobial resistance. Clinicians will be able to tailor therapy based on individual neonatal or child need, offering effective, evidence-based infection management.
Objective
Invasive neonatal infections constitute a significant global public health challenge claiming 6 deaths per 1000 births. The perinatal period is a critical time for invasive neonatal infections. Among these infections, neonatal bacterial infections primarily acquired at the time of delivery through maternal-fetal transmission, remain a leading preventable cause of mortality and morbidity. This public health concern is further exacerbated by the emergence and escalation of antimicrobial resistance (AMR) which is jeopardizing essential benefits made since the discovery of antibiotics especially, the contribution of these drugs to improvements in maternal, neonatal and child mortality. Despite the advancements made in the reduction of morbidity and mortality from neonatal infections, diagnostics still relies primarily on conventional microbiology techniques which are time-consuming and can be inaccurate. Diagnostics with a faster turnaround time would likely improve surveillance in all settings but also enable timely management of infections. FIT-BI is timely as it will enable the development of rapid diagnostic kits allowing real-time bacterial identification and prediction of antimicrobial susceptibility patterns, curbing thereby extensive antibiotic use and AMR; and contributing to the achievement of the sustainable development goals 1 and 3 in an advanced and sustainable manner. This promising undertaking will greatly expand the ER's scientific expertise in multi-disciplinary and state-of-the-art fields including Molecular Biology, Microfluidics and Flow Chemistry, impacting her future career, and positioning her as a leading independent researcher bridging the world of academia and industry. Furthermore, the proposed application has great public potential, as it will contribute to tailoring antibiotic therapy, and improving patient management and prognosis while de-escalating AMR in Europe and beyond.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- natural sciencesbiological sciencesmicrobiology
You need to log in or register to use this function
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European FellowshipsCoordinator
93100 Montreuil
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.